Author Contributions: Drs Toff and Abrams had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Toff, Watt, Gradwell, Batchelor, Goodall, Greaves.
Acquisition of data: Toff, Jones, Ford, Pearse, Watson, Watt, Ross, Batchelor, Meijers, Greaves.
Analysis and interpretation of data: Toff, Jones, Ford, Watson, Watt, Abrams, Meijers, Goodall, Greaves.
Drafting of the manuscript: Toff, Jones, Abrams.
Critical revision of the manuscript for important intellectual content: Ford, Pearse, Watson, Watt, Ross, Gradwell, Batchelor, Meijers, Goodall, Greaves.
Statistical analysis: Toff, Jones, Abrams, Goodall.
Obtained funding: Toff, Goodall, Greaves.
Administrative, technical, or material support: Toff, Jones, Ford, Pearse, Watson, Watt, Ross, Gradwell, Batchelor, Meijers, Goodall, Greaves.
Study supervision: Toff, Ford, Watt, Abrams, Meijers, Goodall, Greaves.
Financial Disclosures: None reported.
Funding/Support: The study was funded by the UK Department for Transport (contract PPAD 9/91/34A), the UK Department of Health, and the European Commission.
Role of the Sponsor: The funding agencies had no involvement in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript.
WRIGHT Project Participants
Scientific Executive Committee: Patrick J. Kesteven, MBBS, PhD, Freeman Hospital, Newcastle upon Tyne, England (chair); Harry R. Büller, MD, PhD, Academic Medical Center, Amsterdam, the Netherlands; Michael Greaves, MD, University of Aberdeen, Aberdeen, Scotland; Shanthi Mendis, MD, World Health Organization, Geneva, Switzerland; Fred Paccaud, MD, PhD, Institute for Social and Preventive Medicine, Lausanne, Switzerland; Frits R. Rosendaal, MD, PhD, Leiden University Medical Center, Leiden, the Netherlands; William D. Toff, MD, University of Leicester, Leicester, England.
Project Monitoring Group: Bruce M. Psaty, MD, PhD, University of Washington, Seattle; Bruce L. Evatt, MD, Centers for Disease Control, Atlanta, Ga; Neil R. Poulter, MBBS, MSc, Imperial College of Science Technology & Medicine, London, England; F. Eric Preston, MD, Hallamshire Hospital, Sheffield, England.
UK Government: Peter Smith, CEng, Department for Transport, and William Maton-Howarth, PhD, Department of Health, London, England.
European Commission: John Wilson and Kris van Balen, Directorate-General for Energy and Transport, European Commission, Brussels, Belgium.
World Health Organization: Derek Yach, MD, Raphael Bengoa, MD, Shanthi Mendis, MD, Dele Abegunde, MD, Mona Nassef, Cardiovascular Diseases, Department of Chronic Diseases and Health Promotion, World Health Organization, Geneva, Switzerland.
Disclaimer: The views expressed in this article are the authors' own and do not necessarily represent the opinions of the other research institutions participating in the project nor the views or policy of the World Health Organization.
Acknowledgment: We gratefully acknowledge the contribution of the volunteers and thank them for their enthusiastic participation. Vijay Chudasama, research assistant in the Department of Cardiovascular Sciences, University of Leicester, England, and Louise R. Mitchell, BSc, research assistant in the Department of Medicine and Therapeutics, University of Aberdeen, Scotland, provided invaluable technical expertise and support. Plasma assays for plasminogen activator inhibitor type-1 and tissue plasminogen activator were developed in the laboratory of Nuala Booth, PhD, and performed by Norma Moore, Institute of Medical Sciences, University of Aberdeen, Scotland. Coagulation assays were performed by personnel at the Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. The staff of the Hyperbaric Medicine Unit at the Aberdeen Royal Infirmary, Aberdeen, Scotland, provided clinical and technical support at the hypobaric chamber facility in Aberdeen. The pressure chamber operators, chamber support staff, and personnel from Altitude Medicine provided clinical and technical support at the chamber facility at the Royal Air Force Centre of Aviation Medicine, Henlow, Bedfordshire, England. We particularly thank Wing Commander Alexander V. Hurley, BA, BM, BSc, DOccMed, DAvMed, Sergeant Kevin P. Roads, and Sergeant Wendell P. Griffiths. We also thank Barbara Alving, MD, National Center for Research Resources, National Institutes of Health, Bethesda, Md, for serving on the project monitoring group; John H. Scurr, BSc, MBBS, FRCS, University College London Hospitals NHS Trust and the Lister Hospital, London, England, for serving on the WRIGHT Scientific Executive Committee; and Claus Curdt-Christiansen, MD, DAvMed, International Civil Aviation Organisation, Montreal, Quebec, for advising the project monitoring group. For the studies carried out at the Royal Air Force Centre of Aviation Medicine, we thank Beckman-Coulter for loan of the flow cytometer and Datex-Ohmeda for loan of the pulse oximeters. None of those named above received any compensation. However, members of the scientific executive committee and the project monitoring group were reimbursed for expenses incurred while attending meetings.
This article was corrected on 5/17/06, prior to publication of the correction in print.